Artios is committed to discovering and developing groundbreaking DDR therapeutics to help patients suffering from a broad range of devastating and difficult-to-treat cancers. Innovation in this space is part of our DNA.

Our executive officers pioneered DDR drug discovery when they co-invented the blockbuster PARP inhibitor olaparib (now marketed as Lynparza® by AstaZeneca) and led successful DDR programs while at KuDOS Pharmaceuticals, a biotechnology firm focused on oncology therapies that was acquired by AstraZeneca. Ever since, we have leveraged our deep scientific, clinical, business, and leadership expertise in DDR discovery to build a world-class platform for developing novel inhibitors of specific DNA repair enzymes. Every day, we are continually pushing the boundaries of what our novel platform can accomplish.

Recent Milestones: ART4215 (PolƟ), Combination (PARPi, and other agents), Ph 1a PK, safety and PD achieved in 2023 ART6043 (PolƟ), Single agent and combinations, Ph 1 study initiated in 2023

Upcoming Milestones: ART0380 (ATR) DDR deficiencies (monotherapy study), Ph 2 expansion data in 2024 ATM null (combination with irinotecan,) Ph 1b POC data in 2024 Platinum resistant ovarian cancer (combination with gemcitabine), Ph 2 POC data in 2024

Products: ART4215 (PolƟ inhibitor), ART6043 (PolƟ inhibitor), ART0380 (ATR inhibitor)

Investors: Omega, TCG, Andera, LSP-EQT, Pfizer, SV Life Sciences, IP Group, Merck Ventures, Arix , Deep Track , Avidity, Piper Heartland , Soleus, Invus, CaaS, Sofinnova, Tetragon, Schroder Adveq, RTW and Novartis Bioventures

Full Company address & contact details: Artios Pharma Ltd, B940 Babraham Research Campus, Cambridge, CB22 3FH, UK. Phone: +44 (0)1223 867900. Email: info@artios.com